Exhibit 99.1

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

Unaudited Consolidated Balance Sheet as of January 31, 2025

	January 31, 2025
Assets
Current assets:
Cash	$	5,362,641
Prepaid expenses		1,142,329
Total current assets		6,504,970
Total assets	$	6,504,970
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	220,202
Notes payable, current		—
Total current liabilities		220,202
Deferred tax liability		—
Derivative financial instruments—warrants		333,189
Total liabilities		553,391
Commitments and contingencies
Stockholders’ equity:
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at December 31, 2024 and 2023, respectively.		855,808
Series C convertible preferred stock, stated value $1,000 per share, 1,688shares issued and outstanding at December 31, 2024 and 2023, respectively.		839,320
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 34,650,681, shares issued and outstanding at January 31, 2025.		663
Additional paid-in capital		242,271,332
Accumulated other comprehensive loss		8,345
Accumulated deficit		(238,023,889	)
Total stockholders’ equity		5,951,579
Total liabilities and stockholders’ equity	$	6,504,970